Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age

Pereira, Allan Andresson Lima; Fernandes, Gustavo dos Santos; Braga, Gabriella T. P.; Marchetti, Katia Regina; Mascarenhas, Cintia do Couto; Gumz, Brenda Pires; Crosara, Marcela; Dib, Luiza; Girardi, Daniel M.; Barrichello, Adriana; Seidler, Heinrich

doi:10.1016/j.clcc.2020.06.004

Cited by 10 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vuik et al [ 37 ] found that poorly differentiated CRCs were more common in the younger group by recruiting 6400 subjects. Pereira et al [ 38 ] analyzed the pathological features of CRC in different groups of age and showed that poorly differentiated tumors was most common in young CRC patients. The results showed that the age difference existed in the moderately and poorly differentiated groups.…”

Section: Discussionmentioning

confidence: 99%

Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria

et al. 2022

View full text Add to dashboard Cite

Background The mortality of colorectal cancer is high, the malignant degree of poorly differentiated colorectal cancer is high, and the prognosis is poor. Objective To screen the characteristic intestinal microbiota of poorly differentiated intestinal cancer. Methods Fecal samples were collected from 124 patients with moderately differentiated CRC and 123 patients with poorly differentiated CRC, and the bacterial 16S rRNA V1-V4 region of the fecal samples was sequenced. Alpha diversity analysis was performed on fecal samples to assess the diversity and abundance of flora. The RDP classifier Bayesian algorithm was used to analyze the community structure. Linear discriminant analysis and Student's t test were used to screen the differences in flora. The PICRUSt1 method was used to predict the bacterial function, and six machine learning models, including logistic regression, random forest, neural network, support vector machine, CatBoost and gradient boosting decision tree, were used to construct a prediction model for the poor differentiation of colorectal cancer. Results There was no significant difference in fecal flora alpha diversity between moderately and poorly differentiated colorectal cancer (P > 0.05). The bacteria that accounted for a large proportion of patients with poorly differentiated and moderately differentiated colorectal cancer were Blautia, Escherichia-Shigella, Streptococcus, Lactobacillus, and Bacteroides. At the genus level, there were nine bacteria with high abundance in the poorly differentiated group, including Bifidobacterium, norank_f__Oscillospiraceae, Eisenbergiella, etc. There were six bacteria with high abundance in the moderately differentiated group, including Megamonas, Erysipelotrichaceae_UCG-003, Actinomyces, etc. The RF model had the highest prediction accuracy (100.00% correct). The bacteria that had the greatest variable importance in the model were Pseudoramibacter, Megamonas and Bifidobacterium. Conclusion The degree of pathological differentiation of colorectal cancer was related to gut flora, and poorly differentiated colorectal cancer had some different bacterial flora, and intestinal bacteria can be used as biomarkers for predicting poorly differentiated CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[64] In addition, the presence of KRAS mutations do not correlate with age. [66] Otherwise, the FIRE-3 trial included patients with KRAS (exon 2) codon 12/13 wild-type mCRC and displayed longer overall survival in patients who received FOLFIRI plus cetuximab compared to FOLFIRI plus bevacizumab. [67] Currently, all CRC patients with stage IV are strongly suggested to be evaluated for -RAS and BRAF mutations to be treated with an anti-EGFR drug, as long as the tumor is not located in the right colon, given those patients do not benefit from that therapy at first-line regardless -RAS status.…”

Section: Colorectal Cancer Biomarkers and Their Impactmentioning

confidence: 99%

Colorectal cancer biomarkers and their impact on the clinical practice

Crespo¹,

Victorino²,

Araujo³

et al. 2021

BJOncology

View full text Add to dashboard Cite

Colorectal cancer (CRC) holds third place in the global ranking of malignancies worldwide. Patients with CRC commonly show distinct outcomes and treatment responses due to their biological features and tumoral biomarkers. This review explores the repertoire of molecular biomarkers in CRC, comprised of chromosomal aberrations and genomic instability and genetic mutations. We also underline the stratification of CRC patients into four clinically defined subsets: CMS1 (MSI, immune); CMS2 (canonical); CMS3 (metabolic); and CMS4 (mesenchymal), as well as novel techniques to be applied very soon in the field, such as cell-free DNA, tumor mutational burden, and microbiome profiling.

show abstract

“…Since elderly patients are more prone to frailty, geriatric syndromes, comorbidities, polypharmacy, and decline of organ function, it was uncertain whether surgery and adjuvant therapy will bene t the elderly patients. Pereira et al reported that BRAF mutations are more frequent among age ≥75 years CRC patients, which means a more aggressive clinical course and poorer prognosis 10 . McCleary et al demonstrated that tumor nuclear CTNNB1 expression associated with higher mortality among elder patients with CRC but not among younger patients 11 .…”

Section: Introductionmentioning

confidence: 99%

Do elderly patients with colorectal cancer benefit from surgery and different therapeutic patterns? A real-world study based on SEER database

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Currently, the treatment guidelines for colorectal cancer (CRC) in elder patients remained unclear. This study aims to investigate whether elder patients (≥70 years) with CRC benefit from surgery and different therapeutic patterns. A total of 90,347 eligible CRC patients older than 70 years were collected from the Surveillance, Epidemiology, and End Results(SEER) database. All the patients were divided into the surgery group and the no-surgery group. After being matched by propensity score matching (PSM) at a 1:1 ratio, 23,930 patients were included in our analysis. The Kaplan-Meier method and log-rank test were applied to compare overall survival (OS) and cancer-specific survival (CSS). In the age-stratified analysis (70–74; 75–79; 80–84; ≥85), the OS and CSS rates of patients in the surgery group were significantly higher than those of patients in the no-surgery group (all P < 0.001). Further analysis showed that surgery plus chemotherapysignificantly improved OS and CSS in elder colon cancer patients with III stage and IV stage compared to surgery alone. Surgery plus chemoradiotherapy significantly improved OS and CSS in elder rectal cancer patients with II stage, III stage and IV stage compared to other therapeutic patterns. Among these CRC patients with aged ≥70 years reported in the SEER database, treatment with surgical resection is significantly associated with an improved OS and CSS. Moreover, adjuvant therapyshowed a significant prognostic advantage for elder advanced CRC patients underwent surgery.

show abstract

Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age

Cited by 10 publications

References 27 publications

Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria

Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria

Colorectal cancer biomarkers and their impact on the clinical practice

Do elderly patients with colorectal cancer benefit from surgery and different therapeutic patterns? A real-world study based on SEER database

Contact Info

Product

Resources

About